Schedule 13G ownership disclosure
Gemini Therapeutics, Inc. /DE
Security class unavailable · CUSIP: 36870G105
Event date: 2022-03-04
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- Unavailable
- Percent of class
- 5.3000%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001567619-22-006680
- Form type
- SC 13G
- Filer
- BML Investment Partners, L.P.
- CIK
- CIK 1373604
- Filed
- Mar 10, 2022
- Reporting period
- Mar 04, 2022
- Description
- Schedule 13G beneficial ownership